Related Experiment Video

Updated: Sep 20, 2026

Cell-based Therapy for Heart Failure in Rat: Double Thoracotomy for Myocardial Infarction and Epicardial Implantation of Cells and Biomatrix
09:11

Cell-based Therapy for Heart Failure in Rat: Double Thoracotomy for Myocardial Infarction and Epicardial Implantation of Cells and Biomatrix

Published on: September 22, 2014

Heart failure: state-of-the-art treatment and new therapeutic options

F Knebel1, G Baumann

  • 1Charitè Campus Mitte, Medical Clinic for Cardiology, Angiology, Pulmology, Berlin, Germany. fabian.knebel@charite.de

Clinical Nephrology
|August 28, 2003
PubMed

Insights

Heart failure management has improved, but new treatments like immunoadsorption and biventricular pacing are under investigation for advanced congestive heart failure (CHF). These options offer hope where traditional therapies are insufficient.

Area of Science:

  • Cardiology
  • Internal Medicine

Background:

  • Heart failure (HF) is a prevalent condition in Western countries with a poor prognosis.
  • Current medical therapies, including beta-blockers, ACE inhibitors, and diuretics, are not universally administered to all chronic heart failure patients.
  • Heart transplantation remains the definitive treatment for end-stage congestive heart failure (CHF).

Purpose of the Study:

  • To summarize current recommendations for medical therapy in heart failure.
  • To explain the mechanisms of novel therapeutic approaches.
  • To present the clinical outcomes of emerging treatments for heart failure.

Main Methods:

  • Review of latest guidelines for heart failure medical therapy.
  • Explanation of the mechanisms of action for immunoadsorption.
  • Analysis of clinical trial data for biventricular pacing.

Main Results:

  • Significant advancements in medical therapy for heart failure have been achieved.
  • Immunoadsorption and biventricular pacing are emerging as promising therapeutic options.
  • These new approaches are being evaluated for their efficacy in managing heart failure.

Conclusions:

  • Despite advances, gaps remain in the optimal medical management of heart failure.
  • Immunoadsorption and biventricular pacing represent innovative strategies for heart failure treatment.
  • Further research and clinical application are needed to establish the role of these new therapies.

More Related Videos

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

Related Concept Videos

Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...